Abbott Laboratories
ABT (NYSE)
Abbott Laboratories, a well-established Dividend Aristocrat, boasts an impressive 54 consecutive years of dividend growth, making it a reliable choice for defensive healthcare exposure in the U.S. market. With a current dividend yield of approximately 2.78%, the stock has faced challenges recently, reflected in a 1-year return of -17.45% and a 5-year return of -12.95%. Analysts maintain a cautious outlook, with a median 12-month price target of $120.00, indicating potential upside from the current levels.
Pros:
- Long history of dividend growth
- Diverse healthcare portfolio
Cons:
- Recent negative returns
- Market competition
Abbott Laboratories may be suitable for conservative investors seeking steady income through dividends, given its long history of dividend growth. However, potential investors should be mindful of its recent underperformance and consider their risk tolerance and investment horizon before making a decision.